A Phase 4 interventional study of doxycycline (Oracea®) 40 mg modified release as monotherapy and doxycycline (Oracea®) 40 mg modified release as add-on therapy in Rosacea, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-25.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.
Among the 12 studies testing doxycycline in Rosacea, this one has the largest enrollment, is the only one that started in 2009, is one of 6 in phase 4, and was the 4th registered.
233 studies on the registry are indexed under Rosacea; 23 are open to participants now.
Browse Rosacea studies →None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 17 Rosacea studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2009.
This study's enrollment of 1,421 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 150 across the 12 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one has the largest enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2009, is one of 9 in phase 4, and was the 7th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
1 of the studies testing doxycycline in Rosacea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oracea as monotherapy
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy
Oracea® as add-on Therapy (Oracea® + Metronidazoles and/or Azelaic Acids and/or Sodium Sulfacetamides
Drug: doxycycline (Oracea®) 40 mg modified release as add-on therapy
Take once daily in the morning
Also known as: Oracea®
Take once daily in the morning
Also known as: Oracea®
Change in Investigator's Global Assessment (IGA) Score From Baseline to Endpoint
Number of participants with a change (Week 12 minus Baseline) in Investigator's Global Assessment (IGA) score. IGA is measured on a scale from 0 - 4 with 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12.
Time frame: Baseline to Week 12
Change in Clinician's Erythema Assessment Scale (CEA) Score From Baseline to Endpoint
Number of participants with a change (Week 12 minus Baseline) in Clinician's Erythema Assessment Scale (CEA) score. Clinician's Erythema Assessment Scale (CEA) is a scale from 0 - 4 with 0 = None; 1 = Mild; 2 = Moderate; 3 = Significant; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12 in CEA.
Time frame: Baaseline to Week 12
Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)
Number of treatment responders at week 12, where response is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (near clear). IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best and 4 being worst.
Time frame: Baseline to Week 12
Dates of recruitment period: First subject was enrolled on April 30, 2009 and the last subject enrolled was on July 31, 2009. Types of location: Investigative sites were located at academic institutions and private physician offices.
| Milestone | Oracea® as Monotherapy | Oracea® as add-on Therapy |
|---|---|---|
| Started | 1197 | 224 |
| Completed | 930 | 187 |
| Not completed | 267 | 37 |
| Withdrew: Adverse event | 65 | 8 |
| Withdrew: Lost to follow-up | 81 | 8 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Protocol violation | 7 | 2 |
| Withdrew: Withdrawal by subject | 86 | 14 |
| Withdrew: Subject failed to return for final visit | 2 | 0 |
| Withdrew: Subject unable to keep follow-up visits | 1 | 0 |
| Withdrew: Final visit completed 4 weeks late | 0 | 1 |
| Withdrew: Subject completed day after study closed | 1 | 0 |
| Withdrew: Family emergency | 1 | 0 |
| Withdrew: Last visit not done - death in family | 1 | 0 |
| Withdrew: Did not meet incl/excl criteria | 1 | 0 |
| Withdrew: Rosacea cleared; subject d/c'd self | 1 | 0 |
| Withdrew: Unable to redeem the drug voucher | 1 | 0 |
| Withdrew: Subject not good candidate for study | 1 | 0 |
| Withdrew: Subject did not return for any visits | 1 | 0 |
| Withdrew: Subject missed several visits/lost meds | 1 | 0 |
| Withdrew: Missed visit 4 and off meds for 65 days | 1 | 1 |
| Withdrew: Scheduled for knee replacement | 0 | 1 |
| Withdrew: Pi complained of inadequate compensation | 3 | 0 |
| Withdrew: Subject lost interest in program | 0 | 1 |
| Withdrew: Bad taste in mouth after taking oracea® | 0 | 1 |
| Withdrew: Death in family | 1 | 0 |
| Withdrew: Lack of efficacy of study product | 2 | 0 |
| Withdrew: Subject not seen by pi at final visit | 1 | 0 |
| Withdrew: No show visit 2; prescription not filled | 1 | 0 |
| Withdrew: Missed multiple visits | 1 | 0 |
| Withdrew: Missed visits rescheduled out of window | 1 | 0 |
| Withdrew: Non-compliant with visits as scheduled | 1 | 0 |
| Withdrew: Subject had history of drug abuse | 1 | 0 |
| Withdrew: Rash on hand | 1 | 0 |
| Withdrew: Visit 4 date out of window | 1 | 0 |
Number of participants with a change (Week 12 minus Baseline) in Investigator's Global Assessment (IGA) score. IGA is measured on a scale from 0 - 4 with 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12.
| participants | Oracea® as Monotherapy | Oracea® as add-on Therapy |
|---|---|---|
| +4 (worsening of rosacea by 4 IGA scale levels | 0 | 0 |
| +3 (worsening of rosacea by 3 IGA scale levels) | 0 | 0 |
| +2 (worsening of rosacea by 2 IGA scale levels) | 0 | 0 |
| +1 (worsening of rosacea by 1 IGA scale level) | 4 | 4 |
| 0 (no change in IGA scale level) | 70 | 11 |
| -1 (improvement of rosacea by 1 IGA scale level | 254 | 42 |
| -2 (improvement of rosacea by 2 IGA scale levels) | 365 | 65 |
| -3 (improvement of rosacea by 3 IGA scale levels) | 123 | 14 |
| -4 (improvement of rosacea by 4 IGA scale levels) | 10 | 4 |
Number of participants with a change (Week 12 minus Baseline) in Clinician's Erythema Assessment Scale (CEA) score. Clinician's Erythema Assessment Scale (CEA) is a scale from 0 - 4 with 0 = None; 1 = Mild; 2 = Moderate; 3 = Significant; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12 in CEA.
| participants | Oracea® as Monotherapy | Oracea® as add-on Therapy |
|---|---|---|
| +4 (worsening of erythema by 4 CEA scale levels) | 0 | 0 |
| +3 (worsening of erythema by 3 CEA scale levels) | 0 | 0 |
| +2 (worsening of erythema by 2 CEA scale levels) | 0 | 0 |
| +1 (worsening of erythema by 1 CEA scale level) | 6 | 2 |
| 0 (no change in CEA scale level) | 97 | 18 |
| -1 (improvement in erythema by 1 CEA scale level) | 415 | 76 |
| -2 (improvement in erythema by 2 CEA scale levels) | 261 | 38 |
| -3 (improvement in erythema by 3 CEA scale levels) | 45 | 6 |
| -4 (improvement of erythema by 4 CEA scale levels) | 2 | 0 |
Number of treatment responders at week 12, where response is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (near clear). IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best and 4 being worst.
| participants | Oracea® as Monotherapy | Oracea® as add-on Therapy |
|---|---|---|
| Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear) | 616 | 106 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oracea® as Monotherapy | — | 5/1,196 (0.4%) | 0/1,196 (0%) |
| Oracea® as add-on Therapy | — | 0/224 (0%) | 0/224 (0%) |
| Event | Oracea® as Monotherapy | Oracea® as add-on Therapy |
|---|---|---|
| Angina pectorisCardiac disorders | 1/1196 | 0/224 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/1196 | 0/224 |
| Cardiac disorderCardiac disorders | 1/1196 | 0/224 |
| Cerebrovascular accidentNervous system disorders | 1/1196 | 0/224 |
| Thrombophlebitis superficialVascular disorders | 1/1196 | 0/224 |
| Age, Continuous(years) | Oracea® as Monotherapy | Oracea® as add-on Therapy | Total |
|---|---|---|---|
| >=18 years | 50.2 ± 13.9 | 53.4 ± 12.9 | 50.7 ± 13.4 |
| Sex: Female, Male(Participants) | Oracea® as Monotherapy | Oracea® as add-on Therapy | Total |
|---|---|---|---|
| Female | 853 | 154 | 1007 |
| Male | 344 | 70 | 414 |
The record gives a start of Apr 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline